Cytokines in the Genesis and Treatment of Cancer, Michael A. Caligiuri; Michael T. Lotze
Автор: Bristow Название: Early Diagnosis and Treatment of Cancer Series: Ovarian Cancer: Expert Consult: Online and Print ISBN: 1416046852 ISBN-13(EAN): 9781416046851 Издательство: Elsevier Science Рейтинг: Цена: 13102.00 р. 18717.00-30% Наличие на складе: Есть (1 шт.) Описание: Packed with practical information designed to cover the range of diagnostic procedures, including pathologic, radiologic, bronchoscopic, and surgical aspects, this title helps you to determine the safest, shortest, least invasive way to reach an accurate diagnosis; stage the disease; and, choose the best initial treatment for early stages.
Автор: Herbert M. Pinedo Название: Drug Resistance in the Treatment of Cancer ISBN: 0521030749 ISBN-13(EAN): 9780521030748 Издательство: Cambridge Academ Рейтинг: Цена: 10453.00 р. Наличие на складе: Есть у поставщика Поставка под заказ.
Описание: Reviews the mechanisms and clinical implications of drug resistance in cancer, considered to be the most significant obstacle to the cure of cancer today. Topics covered include multiple drug resistance and its reversal, topoisomerase drugs, apoptosis, dose intensity and escalation, gene therapy and haematopoietic support.
Автор: Mantovani Название: Pharmacology of Cytokines.2000 ISBN: 0198500424 ISBN-13(EAN): 9780198500421 Издательство: Oxford Academ Рейтинг: Цена: 22176.00 р. Наличие на складе: Поставка под заказ.
Описание: Cytokines are polypeptide mediators which act as communication signals among cells of the immune system as well as among other cells and tissues in the body. They are a heterogeneous and complex group and include interferons, tumor necrosis factor and chemokines. They play a key role in homeostasis and in host defence and are involved in such inflammatory and autoimmune diseases such as rheumatoid arthritis as well as infectious diseases such as HIV infection and septic shock. Modulation of the production and action of cytokines, as well as their exploitation as therapeutic agents, has been the object of intense and competitive research. The pharmacology of cytokines is an exploding area which is entering the clinical arena. This book gives an overview of cytokine research and describes the various approaches that have been taken to develop the pharmacology of these novel mediators. Within the framework of the immunobiology of cytokines, the book examines the interactions with the cytokine system of a variety of compounds ranging from simple synthetic chemicals to biotechnological products . In addition to examining individual agents and approaches, it reviews the pathophysiology o
Описание: After her diagnosis of triple negative breast cancer (TNBC), health journalist Patricia Prijatel did what any reporter would do: start investigating the disease, how it occurs, and how it`s treated. While she learned that important research was emerging, she found a noticeable lack of resources on the disease, which affects 70,000 women a year and differs from hormone-positive breast cancer in important ways, including prognosis and treatment options. InSurviving-Triple Negative Breast Cancer, Prijatel delivers research-based information on the biology of TNBC; the role of genetics, family history, and race; how to navigate treatment options; and a plethora of strategies to reduce the risk of recurrence. Woven throughout the book are stories of women who havefaced TNBC: mothers, wives, daughters, and sisters who went through a variety of medical treatments and then got on with life.
Описание: Cancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK). Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers.
ООО "Логосфера " Тел:+7(495) 980-12-10 www.logobook.ru
